Scil Technology selects proteins with a well described safety and benefit profile to generate innovative products for new indications with a high medical need. To create maximum value, Scil Technology seeks partnerships with companies focusing on complementary products and technologies to co-develop drug candidates.
For a long-term sustainable business, the business unit biologics development focuses on development programs from early research up to clinical phase III. Programs are to be partnered at various stages of development. Today Scil Technology has in its portfolio proprietary R&D programs at different development stages as well as already partnered programs.